Aptevo Therapeutics Inc. (NASDAQ:APVO) issued its earnings results on Thursday. The biotechnology company reported ($0.53) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.08, MarketWatch Earnings reports. The business had revenue of $10.76 million during the quarter. Aptevo Therapeutics had a negative return on equity of 56.35% and a negative net margin of 305.99%.

Shares of Aptevo Therapeutics (NASDAQ APVO) traded down 1.771% during midday trading on Friday, reaching $1.719. The company’s stock had a trading volume of 23,298 shares. The company’s market capitalization is $36.44 million. Aptevo Therapeutics has a 12-month low of $1.60 and a 12-month high of $3.64. The company’s 50-day moving average price is $1.90 and its 200 day moving average price is $1.98.

Separately, ValuEngine downgraded Aptevo Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st.

WARNING: “Aptevo Therapeutics Inc. (APVO) Issues Earnings Results” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/11/aptevo-therapeutics-inc-apvo-issues-earnings-results.html.

About Aptevo Therapeutics

Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.

Receive News & Stock Ratings for Aptevo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics Inc. and related stocks with our FREE daily email newsletter.